Leveraging Data Intelligence for Effective Opportunity Screening and Prioritization in Drug Discovery

Case Study

Challenge

Our biotech client needed an innovative, effective way to identify which binding sites and therapeutic indications they should target for the development of new therapeutic agents for oncological applications.  

However, the traditional approach to periodically screening and prioritization requires significant effort and resources to: 

  • Develop predictive models for target prioritization that aligns with the global strategy of the company and considers the potential clinical and commercial value 
  • Continually monitor the latest advancements in scientific production to systematically review new opportunities over the time 

Scouting and evaluating targets in this way demands considerable resources and requires recurrent efforts for each review. Additionally, failing in even one of these activities undermines the capacity of the R&D team to timely identify suitable opportunities and reduce the time to market to leverage those opportunities. 

Our Solution

Our data analytics and technology experts have developed a customizable, actionable digital solution that support strategic decision-making. Utilizing our business strategists, scientists, and software developers, this tailored solution outlines the best fit for the company’s strategic priorities and capabilities.  

To deliver comprehensive analytics that our client could immediately action on, we followed a multi-step process: 

Step 1: Integrated biological evidence and drug data sources  

  • Identified over 5,000 biological targets and more than 1,000 clinical indications in the company’s top therapeutic areas 
  • Integrated drug and scientific evidence on biological target and indication from seven databases 
  • Cross-referenced information to create a knowledge base of more than 130,000 biological target-indication associations and 12,000 drugs 

Step 2: Developed a prioritization model based on scientific and market evaluations 

  • Defined parameters that condensed the information into a few relevant metrics 
  • Developed scoring criteria and ranking rules for biological target-indication associations  
  • Defined default algorithm weights according to scientific relevance and underlying business potential of each criterium 

Step 3: Provided expert support and indication prioritization   

  • Developed an intuitive, web-based tool that allowed users to explore data, tune model weights, and achieve different prioritization outcomes depending on assumptions 
  • Delivered training sessions to help identify the final prioritized list of associations 
  • Leveraged AI-assisted data mining to prioritize associations through the analysis of clinical, commercial, and health economics endpoints  

Outcome 

The complete, customized solution allows our client to explore the full spectrum of R&D opportunities through the integration of multiple public and private data sources and an actionable prioritization algorithm. With our deep industry knowledge and therapeutic expertise, we can leverage the power of data to develop tailored digital solutions that reduce the burden of data mining and early opportunity assessment. The client can also rely on these additional benefits of our analytics: 

  • Reduction of human-error related risks in data analysis   
  • Reduction of time and financial effort required by manual data gathering and analysis 
  • Enhanced interdepartmental collaboration  
  • Optimized opportunity review process that utilizes continually updated data 

Ready to fuel your decision-making by unlocking the power of data?

Related news

Events September 30, 2022
XV Congresso Nazionale Sihta
We are pleased to share that we will be joining as speakers and sponsors XV Congresso Nazionale Sihta, a key event for Italian Healthcare industry.
Digital Health Real-World Evidence
News September 6, 2022
Alira Health Expands North American Capabilities with the Acquisition of Artisan Healthcare Consulting
The acquisition of Artisan strengthens and extends Alira Health’s Market Access and Management Consulting advisory practices in North America and globally.
Biotech Market Access Pharma Therapeutics
Publications August 25, 2022
Why—and When—to Use a CDMO
Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons. In this article, we explore(...)
CDMO Pharma Research and Development
Multimedia August 1, 2022
Partners in the Continuum of Drug Development
Listen to the new Empowered Patient Podcast with Karen Jagoda as Gabriele Brambilla, Alira Health CEO, discusses novel approach using technology services to actively engage and partner(...)
Decentralized Clinical Trials Digital Health Patient Centric
Publications June 23, 2022
Developing Data Specialist Talent: Collaboration Is Key
Companies across Pharma and MedTech need talented people to cover the range of data-related challenges. Discover what this means for developing talent throughout the industry.
Data Specialist MedTech Pharma
News June 17, 2022
Music Beats Cancer Hosts Reception at BIO International Convention in San Diego
Music Beats Cancer hosted a reception fostering a networking community for innovators working on promising solutions for cancer.
Crowdfunding Patient Centricity Research & Development
News May 11, 2022
Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups
We acquired RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction(...)
MedTech Patient Engagement Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.